PRO-LAD - PsychonautWiki

PRO-LAD

Summary sheet: PRO-LAD
PRO-LAD
PRO-LAD.svg
Chemical Nomenclature
Common names PRO-LAD
Substitutive name 6-Propyl-6-nor-lysergic acid diethylamide
Systematic name (8β)-N,N-Diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide
Class Membership
Psychoactive class Psychedelic
Chemical class Lysergamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 20 µg
Light 50 - 100 µg
Common 100 - 200 µg
Strong 200 - 350 µg
Heavy 350 µg +
Duration
Total 6 - 8 hours
Onset 30 - 45 minutes









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Cannabis
Stimulants
Tramadol
Lithium

N-Propylnorlysergic acid N,N-diethylamide (also known as 6-Propyl-6-nor-lysergic acid diethylamide[1], N-PropylnorLSD[1] or simply PRO-LAD[1]) is a novel psychedelic substance of the lysergamide class. It is a structural analog of LSD and is part of a series of LSD analogs which includes AL-LAD and ETH-LAD.

PRO-LAD was first investigated by Andrew J. Hoffman and David E. Nichols in 1984 as part of a series of LSD analogs.[2] It was later described as an analog of LSD by Alexander Shulgin in the book TiHKAL ("Tryptamines I Have Known and Loved"), in which one report remarks that it is "good for humor, even excellent... very good for clear thinking, although not cosmic-type particularly."[3] It has been sold on the online research chemical market alongside lysergamides like 1P-LSD and AL-LAD as a legal, grey-market alternative to LSD.

Subjective effects are similar to LSD and include open and closed-eye visuals, time distortion, enhanced introspection, ego loss, and euphoria. It has been reported to be around as potent as LSD itself with an active dose reported at between 100 and 200 micrograms.[3]

Very little data exists about the pharmacological properties, metabolism, and toxicity of PRO-LAD, and it has little history of human usage. It is highly advised use harm reduction practices if using this substance.

Chemistry

PRO-LAD, or 6-propyl-6-nor-lysergic acid diethylamide, is a semisynthetic alkaloid of the lysergamide family. PRO-LAD is a chiral compound with two stereocenters at R5 and R8. PRO-LAD, also called (+)-D-PRO-LAD, has an absolute configuration of (5R, 8R).[citation needed] It is a structural analog of lysergic acid, with an N,N-diethylamide functional group bound to RN of the chemical structure. This core polycyclic structure is an ergoline derivative, and has overlapping tryptamine and phenethylamine groups embedded within it (although it is principally classed as a tryptamine). It differs from LSD by the addition of two carbons to the methyl group at R6 of the structure to form a propyl chain. PRO-LAD is also homologous to ETH-LAD, which contains an ethyl substitution at R6 instead of a propyl chain.

PRO-LAD's structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (nor-lysergic acid). Unlike LSD, PRO-LAD does not contain a methyl group substituted at R6 of its nor-lysergic acid skeleton, this is represented by the nor- prefix. Instead, PRO-LAD is substituted at R6 with a propyl group. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound. At carbon 8 of the quinoline a N,N-diethyl carboxamide is bound. PRO-LAD is a derivative of LSD, differing by the addition of two carbons to the methyl group at R6 of the structure to form a propyl chain.

PRO-LAD is also homologous to ETH-LAD, which contains an ethyl substitution at R6 instead of a propyl chain. PRO-LAD is a chiral compound with two stereocenters at R5 and R8. It is also sometimes called (+)-D-PRO-LAD, as an absolute configuration of (5R, 8R).

Pharmacology

 

This pharmacology section is incomplete.

You can help by adding to it.

Further information: Serotonergic psychedelic

PRO-LAD likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from PRO-LAD's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.

As a derivative of LSD, the pharmacodynamic and pharmacokinetic properties of PRO-LAD are similar to those of LSD. However, they are not exactly the same. The addition of two carbons to the methyl group at R6, and the resulting propyl chain may lead to PRO-LAD being absorbed at a slower rate and therefore a differing initial onset and a peak effect. This could be the reason for the higher threshold and common dosages.[4]

Subjective effects

 
This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Multi-sensory effects
 

Transpersonal effects
 

Combination effects

  • Cannabis - When used in conjunction with cannabis, both the visual and cognitive effects of PRO-LAD can be intensified and extended with extreme efficiency. This should be used with caution if one is not experienced with psychedelics. Many users sometimes report a dramatically more intense visual trip when combining it with THC concentrates such as hashish as opposed to cannabis flower. However, this can also amplify the anxiety, confusion and psychosis producing aspects of both substances significantly, so extreme caution with this combination is advised.
  • Dissociatives - When used in combination with dissociatives, the geometry, euphoria, dissociation and hallucinatory effects are often greatly enhanced. Dissociative-induced holes, spaces, and voids while under the influence of PRO-LAD have significantly more vivid visuals than dissociatives alone present, and more intense internal hallucinations and confusion.
  • MDMA - When used in conjunction with MDMA, the physical and cognitive effects of MDMA are amplified. The visual, physical and cognitive effects of PRO-LAD are also intensified with an overwhelming euphoric pleasure manifested through uniquely pleasurable body highs and headspaces, and uniquely colorful and awe-inspiring visuals. It is often recommended to wait at least three to four hours after ingesting PRO-LAD to take MDMA so as to avoid coming down from the latter while peaking on the former, but positive experiences have been reported with all possible timings. The synergy between these substances is unpredictable (and likely neurotoxic)[citation needed], and it is best to start with lower dosages than one would take for both substances individually.
  • Alcohol - This interaction is not typically recommended due to alcohol’s ability to cause dehydration, depression and thought disorganization which can negatively affect a trip if taken in high dosages. This combination is however reasonably safe in low doses and when used responsibly, this can often take the edge off a trip as well as dull its psychedelic effects in a fashion somewhat similar to benzodiazepines, albeit more stressful on the body.
  • Benzodiazepines - When used in combination with benzodiazepines, benzodiazepines can, depending on the dosage, slightly to completely reduce the intensity of the cognitive, physical and visual effects of a PRO-LAD trip. They are very efficient at stopping bad trips at the cost of amnesia and reduced trip intensity. Caution is advised when acquiring them for this purpose due to the very high addiction potential that benzodiazepines possess.
  • Psychedelics - When used in combination with other psychedelics, each drug's physical, cognitive and visual effects intensify and synergize strongly. The synergy between those substances is unpredictable, and for this reason generally not advised. If choosing to combine psychedelics, it is recommended to start with lower dosages than one would take for either substance individually.

Toxicity and harm potential

 

This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.

The toxicity and long-term health effects of recreational PRO-LAD do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because PRO-LAD is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried PRO-LAD suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.

It is strongly recommended that one use harm reduction practices when using this substance.

Dependence and abuse potential

While no formal studies have been conducted, PRO-LAD is likely not habit-forming and it is reasonable to speculate that the desire to use it can actually decrease with repeated administratino. As with most psychedelics, it likely possesses what is considered an intrinsic, self-regulating aspect to it.

Tolerance to the effects of PRO-LAD is built almost immediately after ingestion. After that, it takes about 5-7 days for the tolerance to be reduced to half and 14 days to be back at baseline (in the absence of further consumption). PRO-LAD presents cross-tolerance with all psychedelics, meaning that after the consumption of PRO-LAD all psychedelics will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status

  • Austria: PRO-LAD is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.[citation needed]
  • Germany: PRO-LAD is controlled under the NpSG (New Psychoactive Substances Act)[6] as of July 18, 2019.[4] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[7]
  • Latvia: PRO-LAD is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.[8]
  • Switzerland: On December 1, 2015, Switzerland added PRO-LAD to the list of controlled substances. It is a controlled substance specifically named under Verzeichnis E.[9]
  • United Kingdom: As of January 7, 2015, PRO-LAD is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.[10]

See also

External links

Literature

  • Hoffman, A. J., & Nichols, D. E. (1985). Synthesis and LSD-like discriminative stimulus properties in a series of N (6)-alkyl norlysergic acid N, N-diethylamide derivatives. Journal of Medicinal Chemistry, 28(9), 1252-1255. https://doi.org/10.1021/jm00147a022.
  • Watts, V. J., Mailman, R. B., Lawler, C. P., Neve, K. A., & Nichols, D. E. (1995). LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 118(4), 401-409. https://doi.org/10.1007/BF02245940.
  • Niwaguchi, T., Nakahara, Y., & Ishii, H. (1976). Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds. Yakugaku Zasshi: Journal of the Pharmaceutical Society of Japan, 96(5), 673-678. PMID 987200.
  • Pfaff, R. C., Huang, X., Marona-Lewicka, D., Oberlender, R., & Nichols, D. E. (1994). Lysergamides Revisited. NIDA Research Monograph, 146, 52-73. PMID: 8742794.

References

  1. 1.0 1.1 1.2 "COMPOUND SUMMARY: Pro-lad". National Center for Biotechnology Information. CID 44457803. Retrieved May 5, 2017. 
  2. Hoffman, Andrew J.; Nichols, David E. (1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. ISSN 0022-2623. 
  3. 3.0 3.1 Shulgin, A., & Shulgin, A. (1991). Erowid Online Books: "TIHKAL" - #51. PRO-LAD. Retrieved April 14, 2017.
  4. 4.0 4.1 "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020. 
  5. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039. 
  6. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  7. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019. 
  8. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020. 
  9. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  10. Advisory Council on the Misuse of Drugs (ACMD) (June 10, 2014). "Update of the generic definition for tryptamines" (PDF). Government Digital Service. p. 12. Retrieved January 1, 2020.